{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T09:29:07Z","timestamp":1794907747826,"version":"4.9.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL156247"],"award-info":[{"award-number":["HL156247"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI164561"],"award-info":[{"award-number":["AI164561"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI167003"],"award-info":[{"award-number":["AI167003"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI186662"],"award-info":[{"award-number":["AI186662"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-72991-8","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:36:50Z","timestamp":1778683010000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Engineering B cells to express fully customizable antibodies with enhanced Fc functions"],"prefix":"10.1038","volume":"17","author":[{"given":"Chun","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6872-944X","authenticated-orcid":false,"given":"Atishay","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan-Hua","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsu-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary B.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"O\u2019Dell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Shuman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond W.","family":"Kung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9183-1269","authenticated-orcid":false,"given":"Geoffrey L.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0059-354X","authenticated-orcid":false,"given":"Paula M.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"72991_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/antib9030034","volume":"9","author":"D Zahavi","year":"2020","unstructured":"Zahavi, D. & Weiner, L. Monoclonal antibodies in cancer therapy. Antibodies 9, 34 (2020).","journal-title":"Antibodies"},{"key":"72991_CR2","doi-asserted-by":"publisher","first-page":"e311","DOI":"10.1016\/S1473-3099(22)00311-5","volume":"22","author":"D Focosi","year":"2022","unstructured":"Focosi, D. et al. Monoclonal antibody therapies against SARS-CoV-2. Lancet Infect. Dis. 22, e311\u2013e326 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"72991_CR3","doi-asserted-by":"crossref","unstructured":"Xiang, Y., Zhang, M., Jiang, D., Su, Q. & Shi, J. The role of inflammation in autoimmune disease: a therapeutic target. Front. Immunol. 14, 1267091 (2023).","DOI":"10.3389\/fimmu.2023.1267091"},{"key":"72991_CR4","doi-asserted-by":"crossref","unstructured":"Nahmad, A. D. et al. Engineered B cells expressing an anti-HIV antibody enable memory retention, isotype switching and clonal expansion. Nat. Commun. 11, 5851 (2020).","DOI":"10.1038\/s41467-020-19649-1"},{"key":"72991_CR5","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1038\/s41551-024-01240-4","volume":"8","author":"GL Rogers","year":"2024","unstructured":"Rogers, G. L. et al. Reprogramming human B cells with custom heavy-chain antibodies. Nat. Biomed. Eng. 8, 1700\u20131714 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"72991_CR6","doi-asserted-by":"crossref","unstructured":"Moffett, H. F. et al. B cells engineered to express pathogen-specific antibodies protect against infection. Sci. Immunol. 4, eaax0644 (2019).","DOI":"10.1126\/sciimmunol.aax0644"},{"key":"72991_CR7","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ymthe.2017.11.012","volume":"26","author":"KL Hung","year":"2018","unstructured":"Hung, K. L. et al. Engineering protein-secreting plasma cells by homology-directed repair in primary human B cells. Mol. Ther. 26, 456\u2013467 (2018).","journal-title":"Mol. Ther."},{"key":"72991_CR8","doi-asserted-by":"crossref","unstructured":"Cheng, R. Y.-H. et al. Ex vivo engineered human plasma cells exhibit robust protein secretion and long-term engraftment in vivo. Nat. Commun. 13, 6110 (2022).","DOI":"10.1038\/s41467-022-33787-8"},{"key":"72991_CR9","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1084\/jem.20190287","volume":"216","author":"H Hartweger","year":"2019","unstructured":"Hartweger, H. et al. HIV-specific humoral immune responses by CRISPR\/Cas9-edited B cells. J. Exp. Med. 216, 1301\u20131310 (2019).","journal-title":"J. Exp. Med."},{"key":"72991_CR10","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1016\/j.ymthe.2024.06.004","volume":"32","author":"TF Hill","year":"2024","unstructured":"Hill, T. F. et al. Human plasma cells engineered to secrete bispecifics drive effective in vivo leukemia killing. Mol. Ther. 32, 2676\u20132691 (2024).","journal-title":"Mol. Ther."},{"key":"72991_CR11","doi-asserted-by":"crossref","unstructured":"Huang, D. et al. Vaccine elicitation of HIV broadly neutralizing antibodies from engineered B cells. Nat. Commun. 11, 5850 (2020).","DOI":"10.1038\/s41467-020-20304-y"},{"key":"72991_CR12","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1016\/j.ymthe.2021.09.019","volume":"29","author":"GL Rogers","year":"2021","unstructured":"Rogers, G. L. & Cannon, P. M. Genome edited B cells: a new frontier in immune cell therapies. Mol. Ther. 29, 3192\u20133204 (2021).","journal-title":"Mol. Ther."},{"key":"72991_CR13","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.omtm.2023.02.004","volume":"28","author":"E Vamva","year":"2023","unstructured":"Vamva, E. et al. A lentiviral vector B cell gene therapy platform for the delivery of the anti-HIV-1 eCD4-Ig-knob-in-hole-reversed immunoadhesin. Mol. Ther. Methods Clin. Dev. 28, 366\u2013384 (2023).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"72991_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03187-1","volume":"11","author":"B Luo","year":"2020","unstructured":"Luo, B. et al. Engineering of \u03b1-PD-1 antibody-expressing long-lived plasma cells by CRISPR\/Cas9-mediated targeted gene integration. Cell Death Dis. 11, 973 (2020).","journal-title":"Cell Death Dis."},{"key":"72991_CR15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ymthe.2018.09.017","volume":"27","author":"A-S Kuhlmann","year":"2019","unstructured":"Kuhlmann, A.-S. et al. Long-term persistence of anti-HIV broadly neutralizing antibody-secreting hematopoietic cells in humanized mice. Mol. Ther. 27, 164\u2013177 (2019).","journal-title":"Mol. Ther."},{"key":"72991_CR16","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/s41587-022-01328-9","volume":"40","author":"AD Nahmad","year":"2022","unstructured":"Nahmad, A. D. et al. In vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice. Nat. Biotechnol. 40, 1241\u20131249 (2022).","journal-title":"Nat. Biotechnol."},{"key":"72991_CR17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1146\/annurev-bioeng-082721-024500","volume":"24","author":"G Delidakis","year":"2022","unstructured":"Delidakis, G., Kim, J. E., George, K. & Georgiou, G. Improving antibody therapeutics by manipulating the Fc domain: immunological and structural considerations. Annu. Rev. Biomed. Eng. 24, 249\u2013274 (2022).","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"72991_CR18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3390\/antib9040064","volume":"9","author":"R Liu","year":"2020","unstructured":"Liu, R., Oldham, R., Teal, E., Beers, S. & Cragg, M. Fc-engineering for modulated effector functions\u2014improving antibodies for cancer treatment. Antibodies 9, 64 (2020).","journal-title":"Antibodies"},{"key":"72991_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004552","volume":"10","author":"LE McCoy","year":"2014","unstructured":"McCoy, L. E. et al. Molecular evolution of broadly neutralizing llama antibodies to the CD4-binding site of HIV-1. PLoS Pathog. 10, e1004552 (2014).","journal-title":"PLoS Pathog."},{"key":"72991_CR20","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1084\/jem.20112655","volume":"209","author":"LE McCoy","year":"2012","unstructured":"McCoy, L. E. et al. Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. J. Exp. Med. 209, 1091\u20131103 (2012).","journal-title":"J. Exp. Med."},{"key":"72991_CR21","doi-asserted-by":"crossref","unstructured":"Mount, S. M. A catalogue of splice junction sequences. Nucleic Acids Res. 10, 459\u2013472 (1982).","DOI":"10.1093\/nar\/10.2.459"},{"key":"72991_CR22","doi-asserted-by":"publisher","first-page":"e0130729","DOI":"10.1371\/journal.pone.0130729","volume":"10","author":"SL Ma","year":"2015","unstructured":"Ma, S. L. et al. Whole exome sequencing reveals novel PHEX splice site mutations in patients with hypophosphatemic rickets. PLoS ONE 10, e0130729 (2015).","journal-title":"PLoS ONE"},{"key":"72991_CR23","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1016\/j.immuni.2023.06.019","volume":"56","author":"JM Kastenschmidt","year":"2023","unstructured":"Kastenschmidt, J. M. et al. Influenza vaccine format mediates distinct cellular and antibody responses in human immune organoids. Immunity 56, 1910\u20131926.e7 (2023).","journal-title":"Immunity"},{"key":"72991_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41591-020-01145-0","volume":"27","author":"LE Wagar","year":"2021","unstructured":"Wagar, L. E. et al. Modeling human adaptive immune responses with tonsil organoids. Nat. Med. 27, 125\u2013135 (2021).","journal-title":"Nat. Med."},{"key":"72991_CR25","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41551-024-01179-6","volume":"8","author":"Y Yin","year":"2024","unstructured":"Yin, Y. et al. In vivo affinity maturation of mouse B cells reprogrammed to express human antibodies. Nat. Biomed. Eng. 8, 361\u2013379 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"72991_CR26","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1016\/j.immuni.2023.07.003","volume":"56","author":"W He","year":"2023","unstructured":"He, W. et al. Heavy-chain CDR3-engineered B cells facilitate in vivo evaluation of HIV-1 vaccine candidates. Immunity 56, 2408\u20132424.e6 (2023).","journal-title":"Immunity"},{"key":"72991_CR27","doi-asserted-by":"publisher","first-page":"6181","DOI":"10.1073\/pnas.1203954109","volume":"109","author":"P Smith","year":"2012","unstructured":"Smith, P., DiLillo, D. J., Bournazos, S., Li, F. & Ravetch, J. V. Mouse model recapitulating human Fc\u03b3 receptor structural and functional diversity. Proc. Natl. Acad. Sci. USA 109, 6181\u20136186 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"72991_CR28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jsb.2016.02.001","volume":"194","author":"AA Ahmed","year":"2016","unstructured":"Ahmed, A. A., Keremane, S. R., Vielmetter, J. & Bjorkman, P. J. Structural characterization of GASDALIE Fc bound to the activating Fc receptor Fc\u03b3RIIIa. J. Struct. Biol. 194, 78\u201389 (2016).","journal-title":"J. Struct. Biol."},{"key":"72991_CR29","doi-asserted-by":"crossref","unstructured":"Saunders, K. O. Conceptual approaches to modulating antibody effector functions and circulation half-life. Front. Immunol. 10, 1296 (2019).","DOI":"10.3389\/fimmu.2019.01296"},{"key":"72991_CR30","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/protein\/gzw040","volume":"29","author":"T Schlothauer","year":"2016","unstructured":"Schlothauer, T. et al. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. Protein Eng. Des. Sel. 29, 457\u2013466 (2016).","journal-title":"Protein Eng. Des. Sel."},{"key":"72991_CR31","doi-asserted-by":"publisher","first-page":"6127","DOI":"10.1128\/JVI.00347-16","volume":"90","author":"B Von Bredow","year":"2016","unstructured":"Von Bredow, B. et al. Comparison of antibody-dependent cell-mediated cytotoxicity and virus neutralization by HIV-1 env-specific monoclonal antibodies. J. Virol. 90, 6127\u20136139 (2016).","journal-title":"J. Virol."},{"key":"72991_CR32","doi-asserted-by":"crossref","unstructured":"Bruel, T. et al. Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nat. Commun. 7, 10844 (2016).","DOI":"10.1038\/ncomms10844"},{"key":"72991_CR33","doi-asserted-by":"crossref","unstructured":"Bruel, T. et al. Lack of ADCC breadth of human non-neutralizing anti-HIV-1 antibodies. J. Virol. 91, e02440-16 (2017).","DOI":"10.1128\/JVI.02440-16"},{"key":"72991_CR34","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1038\/s12276-022-00870-5","volume":"54","author":"S Ko","year":"2022","unstructured":"Ko, S. et al. An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies. Exp. Mol. Med. 54, 1850\u20131861 (2022).","journal-title":"Exp. Mol. Med."},{"key":"72991_CR35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nbt.1601","volume":"28","author":"J Zalevsky","year":"2010","unstructured":"Zalevsky, J. et al. Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol. 28, 157\u2013159 (2010).","journal-title":"Nat. Biotechnol."},{"key":"72991_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002493","volume":"15","author":"MR Gaudinski","year":"2018","unstructured":"Gaudinski, M. R. et al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. PLoS Med. 15, e1002493 (2018).","journal-title":"PLoS Med"},{"key":"72991_CR37","doi-asserted-by":"publisher","first-page":"17885","DOI":"10.1074\/jbc.M116.771188","volume":"292","author":"J Yu","year":"2017","unstructured":"Yu, J. et al. A rational approach to enhancing antibody Fc homodimer formation for robust production of antibody mixture in a single cell line. J. Biol. Chem. 292, 17885\u201317896 (2017).","journal-title":"J. Biol. Chem."},{"key":"72991_CR38","doi-asserted-by":"crossref","unstructured":"De Sainte Agathe, J.-M. et al. SpliceAI-visual: a free online tool to improve SpliceAI splicing variant interpretation. Hum. Genom. 17, 7 (2023).","DOI":"10.1186\/s40246-023-00451-1"},{"key":"72991_CR39","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nature14264","volume":"519","author":"MR Gardner","year":"2015","unstructured":"Gardner, M. R. et al. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 519, 87\u201391 (2015).","journal-title":"Nature"},{"key":"72991_CR40","doi-asserted-by":"publisher","first-page":"e1006786","DOI":"10.1371\/journal.ppat.1006786","volume":"13","author":"ME Davis-Gardner","year":"2017","unstructured":"Davis-Gardner, M. E., Gardner, M. R., Alfant, B. & Farzan, M. eCD4-Ig promotes ADCC activity of sera from HIV-1-infected patients. PLoS Pathog. 13, e1006786 (2017).","journal-title":"PLoS Pathog."},{"key":"72991_CR41","doi-asserted-by":"crossref","unstructured":"Fetzer, I. et al. eCD4-Ig variants that more potently neutralize HIV-1. J. Virol. 92, e02011-17 (2018).","DOI":"10.1128\/JVI.02011-17"},{"key":"72991_CR42","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","volume":"278","author":"D Finzi","year":"1997","unstructured":"Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295\u20131300 (1997).","journal-title":"Science"},{"key":"72991_CR43","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/387183a0","volume":"387","author":"T-W Chun","year":"1997","unstructured":"Chun, T.-W. et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387, 183\u2013188 (1997).","journal-title":"Nature"},{"key":"72991_CR44","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1126\/science.278.5341.1291","volume":"278","author":"JK Wong","year":"1997","unstructured":"Wong, J. K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291\u20131295 (1997).","journal-title":"Science"},{"key":"72991_CR45","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.tips.2021.09.009","volume":"42","author":"AB Silver","year":"2021","unstructured":"Silver, A. B., Leonard, E. K., Gould, J. R. & Spangler, J. B. Engineered antibody fusion proteins for targeted disease therapy. Trends Pharmacol. Sci. 42, 1064\u20131081 (2021).","journal-title":"Trends Pharmacol. Sci."},{"key":"72991_CR46","doi-asserted-by":"crossref","unstructured":"Tapia-Galisteo, A., \u00c1lvarez-Vallina, L. & Sanz, L. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies. J. Hematol. Oncol. 16, 83 (2023).","DOI":"10.1186\/s13045-023-01482-w"},{"key":"72991_CR47","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.virol.2014.09.018","volume":"468\u2013470","author":"N Mueller","year":"2014","unstructured":"Mueller, N., Van Bel, N., Berkhout, B. & Das, A. T. HIV-1 splicing at the major splice donor site is restricted by RNA structure. Virology 468\u2013470, 609\u2013620 (2014).","journal-title":"Virology"},{"key":"72991_CR48","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.cell.2008.10.046","volume":"135","author":"Y Yu","year":"2008","unstructured":"Yu, Y. et al. Dynamic regulation of alternative splicing by silencers that modulate 5\u2032 splice site competition. Cell 135, 1224\u20131236 (2008).","journal-title":"Cell"},{"key":"72991_CR49","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/nar\/gkl1050","volume":"35","author":"NN Singh","year":"2006","unstructured":"Singh, N. N., Singh, R. N. & Androphy, E. J. Modulating role of RNA structure in alternative splicing of a critical exon in the spinal muscular atrophy genes. Nucleic Acids Res. 35, 371\u2013389 (2006).","journal-title":"Nucleic Acids Res."},{"key":"72991_CR50","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/antib13020031","volume":"13","author":"K Beckmann","year":"2024","unstructured":"Beckmann, K. et al. Fc\u03b3-receptor-independent controlled activation of CD40 canonical signaling by novel therapeutic antibodies for cancer therapy. Antibodies 13, 31 (2024).","journal-title":"Antibodies"},{"key":"72991_CR51","doi-asserted-by":"publisher","first-page":"12869","DOI":"10.3390\/ijms232112869","volume":"23","author":"I Lang","year":"2022","unstructured":"Lang, I., Zaitseva, O. & Wajant, H. Fc\u03b3Rs and their relevance for the activity of anti-CD40 antibodies. Int. J. Mol. Sci. 23, 12869 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"72991_CR52","doi-asserted-by":"crossref","unstructured":"Yu, J., Song, Y. & Tian, W. How to select IgG subclasses in developing anti-tumor therapeutic antibodies. J. Hematol. Oncol. 13, 45 (2020).","DOI":"10.1186\/s13045-020-00876-4"},{"key":"72991_CR53","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.3390\/pharmaceutics15102402","volume":"15","author":"DT Abdeldaim","year":"2023","unstructured":"Abdeldaim, D. T. & Schindowski, K. Fc-engineered therapeutic antibodies: recent advances and future directions. Pharmaceutics 15, 2402 (2023).","journal-title":"Pharmaceutics"},{"key":"72991_CR54","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nature13300","volume":"509","author":"AD Gitlin","year":"2014","unstructured":"Gitlin, A. D., Shulman, Z. & Nussenzweig, M. C. Clonal selection in the germinal centre by regulated proliferation and hypermutation. Nature 509, 637\u2013640 (2014).","journal-title":"Nature"},{"key":"72991_CR55","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.immuni.2016.02.010","volume":"44","author":"M Kuraoka","year":"2016","unstructured":"Kuraoka, M. et al. Complex antigens drive permissive clonal selection in germinal centers. Immunity 44, 542\u2013552 (2016).","journal-title":"Immunity"},{"key":"72991_CR56","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.ymthe.2020.10.006","volume":"29","author":"KJ Tatiossian","year":"2021","unstructured":"Tatiossian, K. J. et al. Rational selection of CRISPR-Cas9 guide RNAs for homology-directed genome editing. Mol. Ther. 29, 1057\u20131069 (2021).","journal-title":"Mol. Ther."},{"key":"72991_CR57","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1089\/hum.2009.223","volume":"21","author":"M Lock","year":"2010","unstructured":"Lock, M. et al. Characterization of a recombinant adeno-associated virus type 2 reference standard material. Hum. Gene Ther. 21, 1273\u20131285 (2010).","journal-title":"Hum. Gene Ther."},{"key":"72991_CR58","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jcyt.2022.12.003","volume":"25","author":"H Klingemann","year":"2023","unstructured":"Klingemann, H. The NK-92 cell line\u201430 years later: its impact on natural killer cell research and treatment of cancer. Cytotherapy 25, 451\u2013457 (2023).","journal-title":"Cytotherapy"},{"key":"72991_CR59","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nbt0798-677","volume":"16","author":"AM Merchant","year":"1998","unstructured":"Merchant, A. M. et al. An efficient route to human bispecific IgG. Nat. Biotechnol. 16, 677\u2013681 (1998).","journal-title":"Nat. Biotechnol."},{"key":"72991_CR60","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/cr.2016.102","volume":"27","author":"K Liu","year":"2017","unstructured":"Liu, K. et al. Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy. Cell Res. 27, 151\u2013153 (2017).","journal-title":"Cell Res."},{"key":"72991_CR61","doi-asserted-by":"crossref","unstructured":"Llewellyn, G. N. et al. Humanized mouse model of HIV-1 latency with enrichment of latent virus in PD-1+ and TIGIT+ CD4 T cells. J. Virol. 93, e02086-18 (2019).","DOI":"10.1128\/JVI.02086-18"},{"key":"72991_CR62","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","volume":"409","author":"M Sarzotti-Kelsoe","year":"2014","unstructured":"Sarzotti-Kelsoe, M. et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J. Immunol. Methods 409, 131\u2013146 (2014).","journal-title":"J. Immunol. Methods"},{"key":"72991_CR63","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/cyto.a.21084","volume":"79A","author":"J Pollara","year":"2011","unstructured":"Pollara, J. et al. High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytom. A 79A, 603\u2013612 (2011).","journal-title":"Cytom. A"},{"key":"72991_CR64","doi-asserted-by":"crossref","unstructured":"Miller, M. L. & Finn, O. J. Flow cytometry-based assessment of direct-targeting anti-cancer antibody immune effector functions. Methods Enzymol. 632, 431\u2013456 (2020).","DOI":"10.1016\/bs.mie.2019.07.026"},{"key":"72991_CR65","doi-asserted-by":"publisher","first-page":"8966","DOI":"10.1128\/JVI.73.11.8966-8974.1999","volume":"73","author":"A Trkola","year":"1999","unstructured":"Trkola, A., Matthews, J., Gordon, C., Ketas, T. & Moore, J. P. A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J. Virol. 73, 8966\u20138974 (1999).","journal-title":"J. Virol."},{"key":"72991_CR66","doi-asserted-by":"publisher","unstructured":"Rogers, G. L. tasaR: toolbox for amplicon sequencing analysis in R. (version 0.1). [Computer software]. Preprint at Zenodo https:\/\/doi.org\/10.5281\/zenodo.19503673 (2026).","DOI":"10.5281\/zenodo.19503673"},{"key":"72991_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-13-31","volume":"13","author":"AP Masella","year":"2012","unstructured":"Masella, A. P., Bartram, A. K., Truszkowski, J. M., Brown, D. G. & Neufeld, J. D. PANDAseq: paired-end assembler for illumina sequences. BMC Bioinform. 13, 31 (2012).","journal-title":"BMC Bioinform."},{"key":"72991_CR68","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1093\/bioinformatics\/btp450","volume":"25","author":"M Morgan","year":"2009","unstructured":"Morgan, M. et al. ShortRead: a bioconductor package for input, quality assessment and exploration of high-throughput sequence data. Bioinformatics 25, 2607\u20132608 (2009).","journal-title":"Bioinformatics"},{"key":"72991_CR69","doi-asserted-by":"publisher","unstructured":"Pag\u00e8s, H., Aboyoun, P., Gentleman, R. & DebRoy, S. Biostrings: Efficient manipulation of biological strings. https:\/\/doi.org\/10.18129\/B9.bio.Biostrings, R Package Version 2.78.0, https:\/\/bioconductor.org\/packages\/Biostrings (2025).","DOI":"10.18129\/B9.bio.Biostrings"},{"key":"72991_CR70","doi-asserted-by":"crossref","unstructured":"Wickham, H. ggplot2: Elegant Graphics for Data Analysis. (Springer-Verlag New York,2016).","DOI":"10.1007\/978-3-319-24277-4_9"},{"key":"72991_CR71","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1093\/bioinformatics\/btv494","volume":"31","author":"U Bodenhofer","year":"2015","unstructured":"Bodenhofer, U., Bonatesta, E., Horej\u0161-Kainrath, C. & Hochreiter, S. msa: an R package for multiple sequence alignment. Bioinformatics 31, 3997\u20133999 (2015).","journal-title":"Bioinformatics"},{"key":"72991_CR72","doi-asserted-by":"publisher","first-page":"bbac222","DOI":"10.1093\/bib\/bbac222","volume":"23","author":"L Zhou","year":"2022","unstructured":"Zhou, L. et al. ggmsa: a visual exploration tool for multiple sequence alignment and associated data. Brief. Bioinform. 23, bbac222 (2022).","journal-title":"Brief. Bioinform."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72991-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72991-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72991-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:02:48Z","timestamp":1784246568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72991-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["72991"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-72991-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.07.23.666432","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Intellectual property discussed in this paper has been licensed by Be Biopharma from the University of Southern California. P.M.C. is a compensated member of Be Biopharma\u2019s Scientific Advisory Board. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"6401"}}